Pearson's correlation coefficient was used to study the relationships between variables shown in scatterplots using the cor.test function in R. RB1 inactivation status was determined as homozygous if there was a two copy loss or 1 copy loss accompanied by mutation. Single copy loss or mutation only was categorized as heterozygous loss. The CCP activity in each of these groups was compared to the RB1 wild-type group using both pairwise t-tests and pairwise Wilcoxon rank sum tests, using the pairwise.t.test and pairwise.wilcox.test functions in R. The pairwise t-test and pairwise Wilcoxon rank sum test were also used to compare the number of nonsynonymous mutations and percent genome altered in different metastatic tissue sites, and all copy number vs. expression comparisons. Assessments of the proportions of bone or soft tissue metastases with homozygous PTEN cn loss or high gain of AR were performed by Fisher's Exact test using GraphPad Prism version 6.02, GraphPad Software, La Jolla California USA. Duration on carboplatin treatment was compared for percentages of patients harboring a DNA repair defect with those who did not by Kaplan-Meier plot with logrank test using GraphPad Prism version 6.02. Patients with a DNA repair defect were defined as those with any combination of the following criteria: homozygous or heterozygous loss in ATM by copy number loss and/or mutation, homozygous loss of one of the following 15 Fanconi anemia associated genes (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, BRIP1, FANCL, FANCM, PALB2, SLX4, BRCA1) or germline mutation in BRCA2 and/or ATM.